Literature DB >> 26166557

Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma.

Lien N Hoang1, Melissa K McConechy, Martin Köbel, Michael Anglesio, Janine Senz, Malden Maassen, Stefan Kommoss, Bo Meng, Lynne Postovit, Linda E Kelemen, Annette Staebler, Sara Brucker, Bernhard Krämer, Jessica N McAlpine, C Blake Gilks, David G Huntsman, Cheng-Han Lee.   

Abstract

OBJECTIVE: Polymerase epsilon (POLE) is a DNA polymerase with a proofreading (exonuclease) domain, responsible for the recognition and excision of mispaired bases, thereby allowing high-fidelity DNA replication to occur. The Cancer Genome Atlas research network recently identified an ultramutated group of endometrial carcinomas, characterized by mutations in POLE, and exceptionally high substitution mutation rates. These POLE mutated endometrial tumors were almost exclusively of the endometrioid histotype. The prevalence and patterns of POLE mutated tumors in endometrioid carcinomas of the ovary, however, have not been studied in detail.
MATERIALS AND METHODS: In this study, we investigate the frequency of POLE exonuclease domain mutations in a series of 89 ovarian endometrioid carcinomas.
RESULTS: We found POLE mutations in 4 of 89 (4.5%) cases, occurring in 3 of 23 (13%) International Federation of Gynecology and Obstetrics (FIGO) grade 1, 1 of 43 (2%) FIGO grade 2, and 0 of 23 (0%) FIGO grade 3 tumors. All mutations were somatic missense point mutations, occurring at the commonly reported hotspots, P286R and V411L. All 3 POLE-mutated FIGO grade 1 tumors displayed prototypical histology, and the POLE-mutated FIGO grade 2 tumor displayed morphologic heterogeneity with focally high-grade features. All 4 patients with POLE-mutated tumors followed an uneventful clinical course with no disease recurrence; however, this finding was not statistically significant (P = 0.59).
CONCLUSIONS: The low rate of POLE mutations in ovarian endometrioid carcinoma and their predominance within the low FIGO grade tumors are in contrast to the findings in the endometrium.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26166557     DOI: 10.1097/IGC.0000000000000492

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  14 in total

1.  Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups.

Authors:  Carlos Parra-Herran; Jordan Lerner-Ellis; Bin Xu; Sam Khalouei; Dina Bassiouny; Matthew Cesari; Nadia Ismiil; Sharon Nofech-Mozes
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer.

Authors:  Tze-Kiong Er; Yu-Fa Su; Chun-Chieh Wu; Chih-Chieh Chen; Jing Wang; Tsung-Hua Hsieh; Marta Herreros-Villanueva; Wan-Tzu Chen; Yi-Ting Chen; Ta-Chih Liu; Hung-Sheng Chen; Eing-Mei Tsai
Journal:  J Mol Med (Berl)       Date:  2016-02-27       Impact factor: 4.599

Review 3.  The roles of pathology in targeted therapy of women with gynecologic cancers.

Authors:  Rajmohan Murali; Rachel N Grisham; Robert A Soslow
Journal:  Gynecol Oncol       Date:  2017-11-23       Impact factor: 5.482

Review 4.  A panoply of errors: polymerase proofreading domain mutations in cancer.

Authors:  Emily Rayner; Inge C van Gool; Claire Palles; Stephen E Kearsey; Tjalling Bosse; Ian Tomlinson; David N Church
Journal:  Nat Rev Cancer       Date:  2016-02       Impact factor: 60.716

Review 5.  POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologies.

Authors:  Emmanuelle Nicolas; Erica A Golemis; Sanjeevani Arora
Journal:  Gene       Date:  2016-06-16       Impact factor: 3.688

Review 6.  Family A and B DNA Polymerases in Cancer: Opportunities for Therapeutic Interventions.

Authors:  Vinit Shanbhag; Shrikesh Sachdev; Jacqueline A Flores; Mukund J Modak; Kamalendra Singh
Journal:  Biology (Basel)       Date:  2018-01-02

7.  Affinity-purified DNA-based mutation profiles of endometriosis-related ovarian neoplasms in Japanese patients.

Authors:  Masako Ishikawa; Kentaro Nakayama; Kohei Nakamura; Ruriko Ono; Kaori Sanuki; Hitomi Yamashita; Tomoka Ishibashi; Toshiko Minamoto; Kouji Iida; Sultana Razia; Noriyoshi Ishikawa; Satoru Kyo
Journal:  Oncotarget       Date:  2018-02-22

8.  Functional Analysis of Cancer-Associated DNA Polymerase ε Variants in Saccharomyces cerevisiae.

Authors:  Stephanie R Barbari; Daniel P Kane; Elizabeth A Moore; Polina V Shcherbakova
Journal:  G3 (Bethesda)       Date:  2018-03-02       Impact factor: 3.154

9.  A COEUR cohort study of SATB2 expression and its prognostic value in ovarian endometrioid carcinoma.

Authors:  Cécile Le Page; Martin Köbel; Liliane Meunier; Diane M Provencher; Anne-Marie Mes-Masson; Kurosh Rahimi
Journal:  J Pathol Clin Res       Date:  2019-04-20

10.  Frequent POLE-driven hypermutation in ovarian endometrioid cancer revealed by mutational signatures in RNA sequencing.

Authors:  Jaime I Davila; Pritha Chanana; Vivekananda Sarangi; Zachary C Fogarty; S John Weroha; Ruifeng Guo; Ellen L Goode; Yajue Huang; Chen Wang
Journal:  BMC Med Genomics       Date:  2021-06-22       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.